hearing loss

Fierce Pharma

Regeneron ushers in new era with inaugural gene therapy approval

The FDA today approved the company’s Otarmeni, the first gene therapy for a rare genetic form of hearing loss that affects about 50 newborns per year.

Darren Incorvaia Apr 23, 2026 3:22pm

3D illustration of DNA double helix on space background

Lilly pens $1.1B pact to work on hearing loss gene editing med

Jan 28, 2026 7:00am

Regeneron shares updated data on hearing loss gene therapy

Oct 12, 2025 10:18am

Graphic of sound waves entering a persons ear

Lineage tunes up hearing loss transplant with $12M research pact

Aug 26, 2025 11:00am

hearing deaf pediatrics audiologist doctor children

Lilly strengthens RNA pipeline with $1.3B hearing loss pact

May 16, 2025 7:34am

Regeneron gene therapy restores hearing in 10 of 11 children

Feb 24, 2025 3:00pm